The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.

Cell Cycle
Teresa PalomeroA Ferrando

Abstract

Activating mutations in NOTCH1 are the most prominent genetic abnormality in T-cell acute Lymphoblastic Leukemia (T-ALL) and inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as targeted therapy in this disease. However, most T-ALL cell lines with mutations in NOTCH1 fail to respond to GSI therapy. Using gene expression profiling and mutation analysis we showed that mutational loss of PTEN is a common event in T-ALL and is associated with resistance to NOTCH inhibition. Furthermore, our studies revealed that NOTCH1 induces upregulation of the PI3K-AKT pathway via HES1, which negatively controls the expression of PTEN. This regulatory circuitry is evolutionary conserved from Drosophila to humans as demonstrated by the interaction of overexpression of Delta and Akt in a model of Notch-induced transformation in the fly eye. Loss of PTEN and constitutive activation of AKT in T-ALL induce increased glucose metabolism and bypass the requirement of NOTCH1 signaling to sustain cell growth. Importantly, PTEN-null/GSI resistant T-ALL cells switch their oncogene addiction from NOTCH1 to AKT and are highly sensitive to AKT inhibitors. These results should facilitate the development of molecular therapi...Continue Reading

Citations

Apr 6, 2012·Current Hematologic Malignancy Reports·Adele K FieldingDavid I Marks
Oct 22, 2008·Current Oncology Reports·Patrick A Zweidler-McKay
Aug 5, 2011·International Journal of Hematology·Hudan LiuWarren S Pear
Jul 26, 2012·Blood Cancer Journal·N K El-MallawanyM S Cairo
Mar 23, 2010·Nature Medicine·Heather A HimburgJohn P Chute
Jul 18, 2009·Nature Reviews. Cancer·G Paolo Dotto
Apr 22, 2011·Nature Reviews. Cancer·Prathibha RanganathanAnthony J Capobianco
Aug 6, 2013·Journal of Medicinal Food·Chin-Hui SuJuei-Tang Cheng
Dec 26, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Hai ZhengWalden Ai
Mar 19, 2013·Cancer Cell International·Jiasheng HuXiongpeng Zhu
Mar 8, 2013·International Journal of Nanomedicine·Ke WangJian Huang
Jan 18, 2013·World Journal of Gastroenterology : WJG·Ling-Yun GuoDong-Qiang He
Feb 15, 2014·Nature Communications·Eriko TanakaYasuhiko Tomino
Nov 5, 2013·Biochimica Et Biophysica Acta·Weiqiang ZhouShanchun Guo
Feb 23, 2013·ISRN Hematology·Ronit Vogt Sionov
Jun 17, 2014·Advances in Biological Regulation·Fred E BertrandGeorge Sigounas
Jul 12, 2013·Leukemia & Lymphoma·Craig A Portell, Anjali S Advani
Mar 26, 2010·Expert Opinion on Therapeutic Targets·Daoxin MaMing Hou
Aug 13, 2008·Expert Opinion on Therapeutic Targets·Linda S SteelmanJames A McCubrey
Feb 7, 2016·American Journal of Surgery·Kevin M SokolowskiMuthusamy Kunnimalaiyaan
Oct 27, 2015·Apoptosis : an International Journal on Programmed Cell Death·Chong ZengFeiyue Xing
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Jules P P Meijerink
Jul 28, 2010·Biochimica Et Biophysica Acta·Roberta R Ruela-de-SousaGwenny M Fuhler

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.